Kiniksa Pharmaceuticals, Ltd.
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Kiniksa Pharmaceuticals, Ltd.'s past years’ income statements indicate that its last revenue has increased compared to the previous period by 23% to $270,259,000. Profit margin reached 5%. Total operating expenses were $238,931,000.

Profit Margin

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Profit margin
2016 0 -23.97M
2017 0 -64.87M
2018 0 -103.22M
2019 0 -161.86M
2020 0 -161.38M
2021 38.54M -157.92M -409.72%
2022 220.18M 183.36M 83.28%
2023 270.25M 14.08M 5.21%

KNSA Income Statement (2016 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016
Revenue
Revenue
270.25M220.18M38.54M00000
Cost of revenue
56.52M46.96M9.1M3.80M3.27M028K0
Gross profit
213.73M173.21M29.44M-3.80M-3.27M0-28K0
Operating exp.
Research and development
76.09M65.49M99.29M112.04M135.00M86.59M56.35M17.43M
Selling and marketing
00000000
Total operating expenses
238.93M163.44M186.08M157.36M169.96M108.16M65.4M24.00M
Operating income
-25.19M7.37M-156.63M-157.36M-169.96M-108.16M-65.4M-24.00M
Other income (expenses), net
8.54M3.65M97K1.13M6.04M4.71M529K65K
Income before tax
-16.65M11.02M-156.53M-156.22M-163.91M-103.44M-64.87M-23.93M
Income tax expense
-30.73M-172.33M1.38M5.15M-2.04M-214K2K36K
Net income
14.08M183.36M-157.92M-161.38M-161.86M-103.22M-64.87M-23.97M
Earnings per share
Basic EPS
0.22.64-2.3-2.61-2.99-3.49-2-0.74
Diluted EPS
0.22.6-2.3-2.61-2.99-3.49-2-0.74
Data sourceData sourceData sourceData sourceData sourceData source